Revista Espanola de Cardiologia Suplementos最新文献_第10页

Fibrilación auricular en pacientes con dispositivos cardiacos electrónicos implantables 可植入电子心脏装置患者的房颤

Revista Espanola de Cardiologia Suplementos Pub Date : 2016-01-01 DOI: 10.1016/S1131-3587(16)30014-0

Finn Akerström, Marta Pachón, Alberto Puchol, Andrés Sánchez Pérez, Miguel A. Arias

{"title":"Fibrilación auricular en pacientes con dispositivos cardiacos electrónicos implantables","authors":"Finn Akerström, Marta Pachón, Alberto Puchol, Andrés Sánchez Pérez, Miguel A. Arias","doi":"10.1016/S1131-3587(16)30014-0","DOIUrl":"10.1016/S1131-3587(16)30014-0","url":null,"abstract":"<div><p>Atrial fibrillation is the most common arrhythmia seen in clinical practice. Its prevalence has increased substantially in developed countries because of population aging. Atrial fibrillation is the primary cause of cardioembolic stroke and oral anticoagulant therapy can considerably reduce its risk. Moreover, the number of patients with a cardiac implantable electronic device is increasing. Since these devices have the ability to detect heart rhythm alterations and to store electrograms, they are highly effective tools for detecting atrial high rate episodes, which in most patients usually correspond to episodes of atrial fibrillation or, to a lesser extent, to atrial flutter or tachycardia. Numerous studies have shown that episodes of subclinical atrial fibrillation are associated with an increased risk of thromboembolic events, although it has not been possible to demonstrate a temporal relationship between the two. To date, the efficacy of oral anticoagulants in patients with subclinical atrial fibrillation has been assessed in only one clinical trial, with negative results. Therefore, and until more information is available, the clinical decision on whether to start oral anticoagulant therapy in patients with subclinical atrial fibrillation is not straightforward and, at present, such treatment is not supported by solid clinical evidence.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":"16 ","pages":"Pages 47-51"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(16)30014-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56633834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Técnicas de imagen en la fibrilación auricular 心房颤动的成像技术

Revista Espanola de Cardiologia Suplementos Pub Date : 2016-01-01 DOI: 10.1016/S1131-3587(16)30010-3

José Antonio Vázquez de Prada , Leopoldo Pérez de Isla

引用次数: 1

Edoxabán. Propiedades farmacocinéticas y farmacodinámicas 爱德华。药代动力学和药效学特性

Revista Espanola de Cardiologia Suplementos Pub Date : 2016-01-01 DOI: 10.1016/S1131-3587(16)30017-6

Juan Tamargo

{"title":"Edoxabán. Propiedades farmacocinéticas y farmacodinámicas","authors":"Juan Tamargo","doi":"10.1016/S1131-3587(16)30017-6","DOIUrl":"10.1016/S1131-3587(16)30017-6","url":null,"abstract":"<div><p>Edoxaban is a potent, selective, direct, reversible inhibitor of coagulation factor Xa. Because of its mechanism of action, edoxaban prolongs the prothrombin time and the activated partial thromboplastin time and reduces anti-factor-Xa activity. In both in vitro and in vivo models, edoxaban is a more effective antithrombotic than fondaparinux. Given orally, the drug rapidly (i.e. in 1–2 hours) reaches its peak plasma concentration and achieves its maximum effect on various antithrombotic biomarkers (e.g. prothrombin time, activated partial thromboplastin time and anti-factor-Xa activity). Edoxaban (15–150 mg once daily) has a linear pharmacokinetic profile. It is readily absorbed when given orally (the bioavailability is 62%), but, unlike other factor-Xa inhibitors, it exhibits only poor binding to plasma proteins and is not biotransformed via CYP3A4. It is eliminated by biliary and renal routes and has a half-life of 10–14 hours, which enables edoxaban to be administered once daily. Exposure to the drug is independent of age, sex and ethnicity, but increases as the patient's weight and renal function decrease.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":"16 ","pages":"Pages 60-66"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(16)30017-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56633980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Estudios en fase III del edoxabán 依多沙班的第三阶段研究

Revista Espanola de Cardiologia Suplementos Pub Date : 2016-01-01 DOI: 10.1016/S1131-3587(16)30019-X

Iñaki Lekuona Goya

引用次数: 0

¿Se está controlando las complicaciones del TAVI? TAVI并发症是否得到控制?

Revista Espanola de Cardiologia Suplementos Pub Date : 2015-01-01 DOI: 10.1016/S1131-3587(15)30022-4

Enrique Gutiérrez, Rocío Angulo, Jaime Elízaga, Francisco Fernández-Avilés

引用次数: 2

La guía europea de dislipemia. Fortalezas y debilidades 欧洲血脂异常指南。优点和缺点

Revista Espanola de Cardiologia Suplementos Pub Date : 2015-01-01 DOI: 10.1016/S1131-3587(15)70119-6

Eduardo Alegría-Ezquerra , Eduardo Alegría-Barrero , Ana Alegría-Barrero

引用次数: 0

Tratamiento de la insuficiencia cardiaca avanzada en el siglo XXI. El trasplante cardiaco en la encrucijada 21世纪晚期心力衰竭的治疗。心脏移植处于十字路口

Revista Espanola de Cardiologia Suplementos Pub Date : 2015-01-01 DOI: 10.1016/S1131-3587(15)30002-9

Juan F. Delgado Jiménez

引用次数: 0

TAVI: una revolución en cardiología

Revista Espanola de Cardiologia Suplementos Pub Date : 2015-01-01 DOI: 10.1016/S1131-3587(15)30017-0

César Morís, Pablo Avanzas

引用次数: 4

¿Quo vadis, TAVI? 什么是瓦迪斯，塔维?

Revista Espanola de Cardiologia Suplementos Pub Date : 2015-01-01 DOI: 10.1016/S1131-3587(15)30024-8

César Morís, Raquel del Valle

引用次数: 0

Aspectos organizativos contemporáneos del trasplante cardiaco: visión del clínico 心脏移植的当代组织方面:临床医生的观点

Revista Espanola de Cardiologia Suplementos Pub Date : 2015-01-01 DOI: 10.1016/S1131-3587(15)30004-2

Luis Alonso-Pulpón, Javier Segovia

{"title":"Aspectos organizativos contemporáneos del trasplante cardiaco: visión del clínico","authors":"Luis Alonso-Pulpón, Javier Segovia","doi":"10.1016/S1131-3587(15)30004-2","DOIUrl":"10.1016/S1131-3587(15)30004-2","url":null,"abstract":"<div><p>Heart transplantation in Spain achieved maturity some time ago in terms of outcomes and the number of procedures performed. The main limitation has been a lack of suitable donors. This article reviews strategies currently under discussion for achieving progress in the field, whether by increasing the number of donors, by more rational selection of transplant candidates or by better planning at the national level. The emergence of mechanical circulatory assist devices, used either as a complement or an alternative to transplantation, is the single factor that will have the greatest influence on heart transplantation in the future. Heart failure is a common, chronic and complex condition, whose treatment requires the cooperation of different tiers within the health-care system at the national level. Formal regional networks that enable such cooperation must be established, beginning with the adoption of common terminology. Of particular relevance is the network established for the integrated treatment of cardiogenic shock. Finally, the ongoing training of specialists in the field should be recognized officially. The Spanish Society of Cardiology should take the first steps on the regulatory path towards establishing certification in this subspecialty – this will help harmonize practice in the field of heart failure in Spain with that in other developed countries.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":"15 ","pages":"Pages 21-26"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(15)30004-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56632391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1